Clinical Trial Update: BAY14-2222 Continuous Infusion in Surgeries [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BAY14-2222 as a continuous infusion in surgical settings for hemophilia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAY14-2222

Snippet

Sponsor: Bayer | Conditions: Hemophilia | Phase 3 | Status: COMPLETED